Press Releases September 3, 2026 04:05 PM

Alector to Participate in Upcoming Healthcare Conferences

Alector to Present at Major Healthcare Investment Conferences in September 2026

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
ALEC

Alector, Inc., a biotechnology company focused on therapies for neurodegenerative diseases, announced management participation in two upcoming investor healthcare conferences in New York. The presentations will include fireside chats and will be webcast live, highlighting Alector's pipeline and technology such as its proprietary blood-brain barrier platform, aiming to enhance therapeutic delivery for diseases like Alzheimer's and Parkinson's.

Alector to Participate in Upcoming Healthcare Conferences
ALEC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alector will participate in the Cantor Global Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference in September 2026.
  • The company emphasized its focus on neurodegenerative disease therapies using genetics, immunology, and neuroscience.
  • Alector is advancing its proprietary blood-brain barrier platform (ABC) to improve drug delivery and patient outcomes in CNS diseases.

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference 2026 (New York, New York)
Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat

Morgan Stanley 24th Annual Global Healthcare Conference (New York, New York)
Tuesday, September 15, 2026, at 7:00 a.m. ET, fireside chat

A live webcast of each fireside chat will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Alector Contacts

Argot Partners (media)
David Rosen
646-461-6387
[email protected]

Argot Partners (investors)
Laura Perry
212-600-1902
[email protected]


Risks

  • Clinical and regulatory risks associated with developing therapies for neurodegenerative diseases impacting biotech and healthcare sectors.
  • Potential challenges in demonstrating efficacy and safety of new treatments in clinical trials.
  • Dependence on successful market and investor reception during upcoming presentations, which could affect funding and development pace.

More from Press Releases

Tenable Uses OpenAI GPT Cyber Models to Help Defenders Inspect Community-Built AI Components Sep 3, 2026 XTEND Reality Expansion Ltd. and JFB Construction Holdings Complete Business Combination, Raising $110 Million in Total Capital Sep 3, 2026 Freshworks Announces Inducement Grant under Listing Rule 5635(C)(4) of the Nasdaq Stock Market Sep 3, 2026 Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS Sep 3, 2026 Rogers and Quebecor Agree to New 12-Year Sublicensing Deal for National NHL Games in French Sep 3, 2026